



## MiRNA Targets in Cancer: Diagnosis, Prognosis and Treatment

Guest Editor:

**Prof. Dr. Radosław Mlak**

Body Composition Research  
Laboratory in the Department of  
Human Physiology, Medical  
University of Lublin,  
Radziwiłłowska 11, 20-080 Lublin,  
Poland

Deadline for manuscript  
submissions:

**closed (10 February 2023)**

### Message from the Guest Editor

Over the last decade, miRNAs have become one of the most promising biomarkers in cancer. Numerous studies have shown that these short RNA sequences play a crucial role in the neoplastic process, including cell death regulation, proliferation, signalling, and the formation of metastasis. On the basis of changes in the level of miRNA expression, the detection and differentiation of many pathological conditions, including the development of cancer, are possible. Moreover, miRNAs have been indicated as markers of metastasis, treatment outcome predictors (chemosensitivity, radiosensitivity), and prognostic factors in nearly all types of cancers. However, what is the best strategy to search for miRNAs with the highest predictive value? How many promising results have been validated so far and have the previous results been confirmed? How far are we from using individual miRNAs or complete miRNA profiles in routine clinical practice? With your help, we aim to answer these and many other questions in this Special Issue, entitled MiRNA Targets in Cancer: Diagnosis, Prognosis and Treatment. Research articles and comprehensive reviews are welcome in this Special Issue.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. David Alan Rizzieri

1. Novant Health Cancer  
Institute, Winston-Salem, NC  
27103, USA  
2. Division of Hematologic  
Malignancies and Cellular  
Therapy, Duke University,  
Durham, NC 27710, USA

## Message from the Editor-in-Chief

*Journal of Personalized Medicine (JPM; ISSN 2075-4426)* is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, ‘omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

**Journal Rank:** JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (*Medicine (miscellaneous)*)

## Contact Us

---

*Journal of Personalized Medicine*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/jpm](http://mdpi.com/journal/jpm)  
[jpm@mdpi.com](mailto:jpm@mdpi.com)  
[X@JPM\\_MDPI](https://twitter.com/JPM_MDPI)